Carrier Effect in Development of Rifampin Loaded Proliposome for Pulmonary Delivery: A Quality by Design Study
Purpose: Pulmonary tuberculosis (TB) is a worldwide life-threatening infection. Therecommended anti-TB regimen contains oral administration of classical first-line drugs suchas rifampin for 6-24 months which often leads to low patient compliance due to high adverseeffects; therefore, lung localized...
Main Authors: | Elahehnaz Parhizkar, Delaram Sadeghinia, Hamed Hamishehkar, Shadi Yaqoubi, Ali Nokhodchi, Shohreh Alipour |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2022-03-01
|
Series: | Advanced Pharmaceutical Bulletin |
Subjects: | |
Online Access: | https://apb.tbzmed.ac.ir/PDF/apb-12-336.pdf |
Similar Items
-
Levofloxacin-Proliposomes: Opportunities for Use in Lung Tuberculosis
by: Teerapol Srichana, et al.
Published: (2012-08-01) -
Carrier-Free Inhalable Dry Microparticles of Celecoxib: Use of the Electrospraying Technique
by: Azin Jahangiri, et al.
Published: (2023-06-01) -
Development of Paclitaxel Proliposomal Dry Powder Inhaler (PTX-PLM-DPI) by Freeze-Drying Method for Lung Cancer
by: Chinmoyee Borah, et al.
Published: (2024-03-01) -
Proliposomes: an approach for the development of stable liposome
by: Namita Singh, et al.
Published: (2020-03-01) -
Aliskiren Hemifumarate Proliposomes for Improved Oral Drug Delivery: Formulation Development, In Vitro and In Vivo Permeability Testing
by: Priyanka Kunamaneni, et al.
Published: (2022-07-01)